Best Available Copy

AD

MIC FALE COPY

AD-A231 412

# HUMAN IMMUNE RESPONSE TO HTLV-III VIRUS INFECTION IN ACQUIRED IMMUNODEFICIENCY SYNDROME

ANNUAL REPORT

FRANCIS A. ENNIS



NOVEMBER 10, 1988

Supported by

U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND Fort Detrick, Frederick, Maryland 21701-5012

Contract No. DAMD17-86-C-6279

University of Massachusetts Medical School 55 Lake Avenue North Worcester, Massachusetts 01655

Approved for public release; distribution unlimited

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents

20030210003

000 <u>1</u> 1000

SECURITY CLASSIFICATION OF THIS PAGE REPORT DOCUMENTATION					N PAGE			Form Approved
1. 950097 5	SCUPITY CLAS					AAA DWING C		OMB No. 0704-
1a. REPORT SECURITY CLASSIFICATION Unclassified					16. RESTRICTIVE MARKINGS			
28. SECURITY CLASSIFICATION AUTHORITY					3. DISTRIBUTION / AVAILABILITY OF REPORT Approved for public release			
26. DECLASSIFICATION / DOWNGRADING SCHEDULE					distribution unlimited			
4. PERFORMING ORGANIZATION REPORT NUMBER(S)					,			
4. PERFURMIT	NG UNGANIZA	TION REPO	ORT NUMB	ER(S)	5. MONITORING	ORGANIZATION F	EPORT NUME	IER(S)
6. NAME OF	PERFORMING	ORGANI7	ATION	66. OFFICE SYMBOL	73. NAME OF M	ONITORING ORGA	NIZATION	
University of Massachusetts (If applicable)								
	1 School (City, State, ar	d ZIP Cod	(e)	1	Zh ADORESS (C)	ty, State, and ZIP	Contal	
	Avenue No				VO. AUDRESS (CA	ry, state, and zir		
Worcester	, MA 01	655						
Sa. NAME OF	FUNDING / CP	ONSORING		85. OFFICE SYMBOL		T INSTRUMENT ID		MI 18482 -
ORGANIZ	Ba. NAME OF FUNDING/SPONSORING Bb. OFFICE SYMBOL   ORGANIZATION US Army Medical (if applicable)   Research & Development Command (if applicable)					86-C-6279		NUMBER
SC ADDRESS (	City, State, and	d ZIP Code	)		10. SOURCE OF F	UNDING NUMBER	ls.	**
Fort Detr	ick, Fred	erick.	MD 23	1701-5012	PROGRAM ELEMENT NO.	PROJECT	TASK NO.	WORK U
	·				63105A	NO. <u>3M2-</u> 63105DH29	AD	01
12. PERSONAL Ennis, Fra	AUTHOR(S) ancis, A.			IV-III Virus Inf				
12. PERSONAL	AUTHOR(S) ancis, A. REPORT	1:	35. TIME C		ection in Ac 14. Date of Repo November	RT (Year, Month,		ncy Syndro GE COUNT 6
12. PERSONAL Ennis, Fra 13a. TYPE OF	AUTHOR(S) ancis, A. REPORT	]1:	35. TIME C	OVERED	14. DATE OF REPO	RT (Year, Month,		GE COUNT
12. PERSONAL Ennis, Fra 13. TYPE OF Annua 16. SUPPLEME	AUTHOR(S) ancis, A. REPORT al NTARY NOTAT		35. TIME C	OVERED <u>/87 </u> to <u>10/8</u> 8	14. DATE OF REPO November	RT (Year, Month, 10,1988	0oy) 15. PA	GE COUNT
12. PERSONAL Ennis, Fra 13a. Type Of Annua	AUTHOR(S) ancis, A. REPORT		36. TIME C	OVERED (87TO10/88 18. SUBJECT TERMS (	14. DATE OF REPO November Continue on reverse	RT (Year, Month, 10, 1988 e if necessar - and	Day) 15. PA	IGE COUNT 6 Nock number)
12. PERSONAL Ennis, Fra 13. TYPE OF Annua 16. SUPPLEME 17. FIELD 06	AUTHOR(S) ancis, A. REPORT al NTARY NOTAT COSATI GROUP () }		35. TIME CI FROM <u>10/</u>	OVERED (87TO10/88 18. SUBJECT TERMS (	14. DATE OF REPO November Continue on reverse	RT (Year, Month, 10, 1988 e if necessar - and	Day) 15. PA	IGE COUNT 6 Nock number)
12. PERSONAL Ennis, Fra 13. TYPE OF Annua 16. SUPPLEME 17. FIELD 06 06	AUTHOR(S) ancis, A. REPORT al NTARY NOTAT COSATI GROUP () } 1 }		35. TIME CI FROM <u>10/</u> GROUP	OVERED <u>/87 TO 10/88</u> 18. SUBJECT TERMS ( J AIDS:	14. DATE OF REPO November Continue on reverse HIV-1; Reti	RT (Year, Month, 10, 1988 e if necessar - and	Day) 15. PA	IGE COUNT 6 Nock number)
12. PERSONAL Ennis, Fra 13. TYPE OF Annua 16. SUPPLEME 17. FIELD 06 06	AUTHOR(S) ancis, A. REPORT al NTARY NOTAT COSATI GROUP () } 1 } (Continue on		3b. TIME C FROM <u>10/</u> GROUP	OVERED (87TO10/88 18. SUBJECT TERMS ( AIDS: and identify by block in	14. DATE OF REPO November Continue on reverse HIV-1; Reti RA 1	RT (Year, Month, 10, 1988 e if necessar - and rovirus, Ler	Dayj 15. PA	GE COUNT 6 Noct number) Immunolog
12. PERSONAL Ennis, Fr: 13. TYPE OF Annua 16. SUPPLEME 17. FIELD ()6 ()6 19. ABSTRACT hu	AUTHOR(S) ancis, A. REPORT al NTARY NOTAT COSATI GROUP () } ] } (Continue on The pu imans to H	CODES SUB-C reverse if arpose c Juman Ta	3b. TIME CI FROM <u>10</u> / SROUP	OVERED (87TO10/88 18. SUBJECT TERMS ( AIDS: and identify by block in research program ficiency Virus (	14. DATE OF REPO November Continue on reverse HIV-1; Reti 	RT (Year, Month, 10, 1988 e if necessary and rovirus, Ler te immune r lon and the	Dayj 15. PA	GE COUNT 6 Wock number Immunolo 0f the
12. PERSONAL Ennis, Fr: 13. TYPE OF Annua 16. SUPPLEME 17. FIELD 06 ()6 19. ABSTRACT hu Ac	AUTHOR(S) ancis, A. REPORT al NTARY NOTAT COSATI GROUP ()} ]} (Continue on The pu imans to H equired Im	CODES SUB-C reverse if arpose of Juman It amune Do	3b. TIME C FROM <u>10/</u> SROUP Inecessary of the mmunode eficien	OVERED <u>(87</u>	14. DATE OF REPO November Continue on reverse HIV-1; Reti RA 1 mber) m is to defin (HIV) infecti DS). Immunod	RT (Year, Month, 10, 1988 e if necessary and rovirus, Ler ne immune r lon and the leficiency c	Day; 15. PA i Mennity by t ntivirus, euponses cause of aused by	GE COUNT 6 Wock number) Immunolog
12. PERSONAL Ennis, Fr: 13. TYPE OF Annua 16. SUPPLEME 17. FIELD 06 06 05 19. ABSTRACT hu Ac	AUTHOR(S) ancis, A. REPORT al NTARY NOTAT COSATI GROUP ()} ]} (Continue on The pu imans to H equired Im ifections	CODES SUB-C reverse if arpose of Juman It amune Do may be	3b. TIME CO FROM 10/ SROUP Inecessary of the mmunode eficien due to	OVERED <u>(87 TO 10/88</u> 18. SUBJECT TERMS ( AIDS: and identify by block in research program ficiency Virus ( cy Syndrome (AII immune mediated	14. DATE OF REPO November Continue on reverse HIV-1; Reti RA 1 wmber) a is to defin (HIV) infacti DS). Immunod i iysis (by a	RT (Year, Month, 10, 1988 e if necessary and rovirus, Ler ne immune r lon and the leficiency c antibody and	Dayj 15. PA Mennity by t ntivirus, euponses cause of aused by /or HIV	GE COUNT 6 Wock number) Immunolog
12. PERSONAL Ennis, Fr: 13. TYPE OF Annua 16. SUPPLEME 17. FIELD 06 06 06 19. ABSTRACT hu Ac in sp	AUTHOR(S) ancis, A. REPORT al NTARY NOTAT COSATI GROUP ()} ]} (Continue on The pu imans to H equired Im ifections pecific cy	CODES SUB-C reverse if arpose of luman In mune Do may be rtotoxid	3b. TIME CO FROM 10/ SROUP Decessory of the mmunode eficien due to c T lym	OVERED <u>(87</u>	14. DATE OF REPO November Continue on reverse HIV-1; Reti RA 1 wmber) a is to defin (HIV) infacti DS). Immunod i lysis (by a of infected	RT (Year, Month, 10, 1988 e if necessary and rovirus, Ler ne immune r lon and the leficiency c intibody and macrophages	Day) 15. PA Mennity by t ativirus, esponses cause of aused by /or HIV and T4	GE COUNT 6 Nock number) Immunolog of the HIV
12. PERSONAL Ennis, Fr: 13. TYPE OF Annua 16. SUPPLEME 17. FIELD 06 06 06 19. ABSTRACT hu Ac in sp ly	AUTHOR(S) ancis, A. REPORT al NTARY NOTAT COSATI GROUP ()} ]) (Continue on The pu mans to H quired Im ifections pecific cy mphocytes reded for	CODES SUB-C	3b. TIME C FROM 10/ SROUP Inecessary of the mmunode eficien due to c T lym defini al appr	OVERED <u>18. SUBJECT TERMS (</u> AIDS: and identify by block in research program ficiency Virus ( cy Syndrome (AII immune mediated phocytes [CTL]) tions of these is oaches for there	14. DATE OF REPO November Continue on reverse HIV-1; Reti RA 1 (HIV) information (HIV) information (HI	RT (Year, Month, 10, 1988 e if necessary and rovirus, Ler non and the leficiency c intibody and macrophages uses to HIV ention.	Day) 15. PA Intentify by to ativirus, responses cause of aused by /or HIV and T4 virus are	GE COUNT 6 Nock number) Immunolog of the HIV
12. PERSONAL Ennis, Fr: 13. TYPE OF Annua 16. SUPPLEME 17. FIELD 06 06 06 19. ABSTRACT hu Ac in sp ly ne	AUTHOR(S) ancis, A. REPORT al NTARY NOTAT COSATI GROUP ()} ()} ()} (Continue on The pu mans to H cquired Im fections weific cy mphocytes weded for Since	CODES SUB-C SUB-C SUB-C Iuman In mune Do may be vtotoxic . The ration the pro	3b. TIME C FROM 10/ SROUP Inecessary of the mmunode eficien due to c T lym defini al appr oject b	OVERED (87TO10/88 18. SUBJECT TERMS ( AIDS: and identify by block in research program ficiency Virus ( cy Syndrome (AII immune mediated phocytes [CTL]) tions of these is oaches for there egan in October,	14. DATE OF REPO November Continue on reverse HIV-1; Reti RA 1 umber) a is to defin (HIV) infreti DS). Immunod i lysis (by a of infected immune respon apy and preve 1986, we ha	RT (Year, Month, 10, 1988 e if necessary and rovirus, Ler ton and the leficiency c intibody and macrophages ises to HIV intion.	Dey) 15. PA Intentity by the Ativirus, esponses cause of aused by /or HIV and T4 virus are d an intention	GE COUNT 6 Nock number) Immunolog of the HIV
12. PERSONAL Ennis, Fr: 13. TYPE OF Annua 16. SUPPLEME 17. FIELD 06 06 06 19. ABSTRACT hu Ac in sp ly ne	AUTHOR(S) ancis, A. REPORT al NTARY NOTAT COSATI GROUP ()} ()} ()} (Continue on The put mans to H cquired Im (fections becific cy mphocytes beded for Since rogram of	CODES SUB-C	3b. TIME C FROM 10/ SROUP Inecessary of the mmunode eficien due to c T lym defini al appr oject b ch proj	OVERED <u>18. SUBJECT TERMS (</u> AIDS: and identify by block in research program ficiency Virus ( cy Syndrome (AII immune mediated phocytes [CTL]) tions of these is oaches for there	14. DATE OF REPO November Continue on reverse HIV-1; Reti RA 1 umber) a is to defin (HIV) infreti DS). Immunod i lysis (by a of infected immune respon apy and preve , 1986, we ha experimental	RT (Year, Month, 10, 1988 e if necessary and rovirus, Ler ton and the leficiency c intibody and macrophages ises to HIV intion.	Dey) 15. PA Intentity by the Ativirus, esponses cause of aused by /or HIV and T4 virus are d an intention	GE COUNT 6 Nock number) Immunolo of the HIV
12. PERSONAL Ennis, Fr: 13. TYPE OF Annua 16. SUPPLEME 17. FIELD 06 06 06 19. ABSTRACT hu Ac in sp ly ne	AUTHOR(S) ancis, A. REPORT al NTARY NOTAT COSATI GROUP ()} ()} ()} (Continue on The put mans to H cquired Im (fections becific cy mphocytes beded for Since rogram of	CODES SUB-C	3b. TIME C FROM 10/ SROUP Inecessary of the mmunode eficien due to c T lym defini al appr oject b ch proj	OVERED (87TO10/88 18. SUBJECT TERMS ( AIDS: and identify by block in research program ficiency Virus ( cy Syndrome (AII immune mediated phocytes [CTL]) tions of these is oaches for there egan in October, ects to develop	14. DATE OF REPO November Continue on reverse HIV-1; Reti RA 1 umber) a is to defin (HIV) infreti DS). Immunod i lysis (by a of infected immune respon apy and preve , 1986, we ha experimental	RT (Year, Month, 10, 1988 e if necessary and rovirus, Ler ton and the leficiency c intibody and macrophages ises to HIV intion.	Dey) 15. PA Intentity by the Ativirus, esponses cause of aused by /or HIV and T4 virus are d an intention	GE COUNT 6 Nock number) Immunolog of the HIV
12. PERSONAL Ennis, Fr: 13. TYPE OF Annua 16. SUPPLEME 17. FIELD 06 06 06 06 19. ABSTRACT hu Ac in sp 1y ne pr de	AUTHOR(S) ancis, A. REPORT al NTARY NOTAT COSATI GROUP ()} ]) (Continue on The pu mans to H quired Im fections becific cy mphocytes eded for Since fining th	CODES SUB-C SUB-C SUB-C SUB-C SUB-C Prose of Suman In mune Do may be vtotoxic amune Do may be vtotoxic	3b. TIME C FROM 10/ SROUP Decessory of the mmunode eficien due to e T lym defini al appr oject b ch proj ne resp	OVERED (87TO10/88 18. SUBJECT TERMS ( AIDS: and identify by block in research program ficiency Virus ( cy Syndrome (AII immune mediated phocytes [CTL]) tions of these is oaches for there egan in October, ects to develop	14. DATE OF REPO November Continue on reverse HIV-1; Reti RA 1 umber) a is to defin (HIV) infreti DS). Immunod i lysis (by a of infected immune respon apy and preve , 1986, we ha experimental	RT (Year, Month, 10, 1988 e if necessary and rovirus, Ler ton and the leficiency c intibody and macrophages ises to HIV intion.	Dey) 15. PA Intentity by the activirus, responses cause of aused by /or HIV and T4 virus are d an intention	GE COUNT 6 Nock number) Immunolog of the HIV
12. PERSONAL Ennis, Fr: 13. TYPE OF Annua 16. SUPPLEME 17. FIELD 06 06 06 06 19. ABSTRACT hu Ac in sp 1y ne pr de	AUTHOR(S) ancis, A. REPORT al NTARY NOTAT COSATI GROUP () } ] ] (Continue on The pu mans to H quired Im fections recific cy mphocytes reded for Since rogram of fining th	CODES SUB-C SUB-C SUB-C SUB-C SUB-C Arpose of Arpose of Arborne of Arbor	3b. TIME CO FROM 10/ SROUP Decessory of the mmunode eficien due to c T lym defini al appr oject b ch proj ne response	OVERED <u>18. SUBJECT TERMS (</u> AIDS: and identify by block in research program ficiency Virus ( cy Syndrome (AII immune mediated phocytes [CTL]) tions of these is oaches for there egan in October, ects to develop onses of humans	14. DATE OF REPO November Continue on reverse HIV-1; Reti RA 1 (HIV) information (HIV) information (HI	RT (Year, Month, 10, 1988 e if necessary and rovirus, Ler fon and the leficiency c intibody and macrophages ises to HIV ention. ive develope systems re	Day) 15. PA Mennity by E Ativirus, esponses cause of aused by /or HIV and T4 virus are d an inte quired fo	GE COUNT 6 Nock number) Immunolog of the HIV
12. PERSONAL Ennis, Fr: 13. TYPE OF Annua 16. SUPPLEME 17. FIELD 06 06 06 19. ABSTRACT hu Ac in sp ly ne pr de 20. DISTRIBUT UNCLASS 222. NAME OF	AUTHOR(S) ancis, A. REPORT al NTARY NOTAT COSATI GROUP () } ] ] (Continue on The pu mans to H quired Im Ifections recific cy mphocytes reded for Since rogram of fining th	CODES SUB-C	3b. TIME CO FROM 10/ SROUP Decessory of the mmunode eficien due to c T lym defini al appr oject b ch proj ch proj ch proj ch proj ch stract SAME AS R	OVERED <u>18. SUBJECT TERMS (</u> <u>AIDS:</u> and identify by block in research program ficiency Virus ( cy Syndrome (AII immune mediated phocytes [CTL]) tions of these is oaches for there egan in October, ects to develop onses of humans	14. DATE OF REPO November Continue on reverse HIV-1; Reti RA 1 wmber) a is to defin (HIV) inf*cti DS). Immunod i iysis (by a of infected immune respon apy and preve , 1986, we ha experimental to HIV.	RT (Year, Month, 10, 1988 e if necessary and rovirus, Ler for and the leficiency c intibody and macrophages ises to HIV ention. ive develope systems re	Day) 15. PA	GE COUNT 6 Nock number) Immunolog of the HIV egrated or

¥ .

#### A. Summary

The purpose of the research program is to define immune responses of humans to Human Immunodeficiency Virus (HIV-1) infection and the cause of the Acquired Immune Deficiency Syndrome (AIDS). Immunodeficiency caused by HIV infections may be due to immune mediated lysis (by antibody and/or HIV specific cytotoxic T lymphocytes [CTL]) of infected macrophages and T4 lymphocytes. Enhanced infection of macrophages and other Fc receptor bearing cells by virus-antibody complexes may contribute to the pathogenesis of HIV-1 infections. The definitions of these immune response to HIV are needed for rationa, approaches for therapy and prevention.

Since the project began in October, 1986, we have developed an integrated program of research projects to develop experimental systems required for defining the immune responses of humans to HIV.

## B. Foreword

- a) Copyright material NA
- b) Limited distribution material NA
- c) Commercial organizations, etc NA
- d) Animal experimentation NA
- e) For the protection of human subjects the investigators have adhered to policies of applicable Law 45CFR46.
- f) The investigators have abided by the NIH Guidelines for Research involving recombinant DNA Molecules (April 1982) and the Accession Fo NTIS GRARI Administrative Practices Supplement. DTIC TAB

1

ACCOS	SIOD FOF							
NTIS	GRANI							
DTIC	TAB	ā						
Unann	ounced	Ō						
Justi	fication_							
H <b>v</b>								
Distribution								
Availability Codes								
	Avail and	i/or						
Dist	Special	L j						
а <b>Т</b> .	1							
V/1	-							
. <b>n</b>								
	<u>ا ا ا ا ا ا ا ا ا ا ا ا ا ا ا ا ا ا ا </u>							

## C. Body of Report

#### 1. Antibody-enhanced infection by HIV-1 via Fc Receptor-Mediated Entry.

a) Brief summary

Cells of macrophage lineage can be infected by HIV-1 via three possible mechanisms. Virus can attach to the CD4 receptor and infect macrophages similar to the mechanism of infection of CD4 + cells. Macrophages could pinocytose the virus particle. In addition, virus could enter macrophages complexed to antibody via binding to Fo receptors for IgO or C3b. We have recently reported evidence that the serum of some HIV-1 antibody positive individuals can complex with HIV-1 and augment HIV-1 infection of a human monocytic cell line, U937. This enhancement of infection occurs at serum dilutions beyond the neutralization endpoint, and is detectable at very high dilutions in some sera, and mediated by Fc receptors.

In the coming year, we will extend these data by measuring levels of neutralizing and enhancing antibody in sera selected from:

## b) Studies Planned for this year

1) A cohort of individuals in a high risk group for HIV-1 infection have been prospectively followed at Johns Hopkins from 1983 in a study of the epidemiology of HIV-1 infection. Selected sets of sera have been given to us under code. These sera were obtained from individuals in the group some of whom have become infected with HIV-1 and were followed clinically. Our results will be given to the clinical epidemiologists performing the study and they may provide some evidence for or against a possible role for infection-enhancing antibodies in the progression of HIV-1 infections.

2

We have been asked by Dr. Wayne Koff, Director, Prevention 2) Branch, AIDS Program, NIAID, to study under code for neutralizing and enhancing antibodies selected sera from some volunteers who have been injected with baculovirus expressed HIV gp 160 experimental vaccine. It is important to avoid the induction of infection enhancing antibodies in developing candidate experimental HIV-1 vaccines, and our results should provide useful information concerning this aspect of HIV-1 vaccine development. We will initiate studies to identify the viral epitopes 3) responsible for enhancement using monoclonal antibodies and polyclonal antisera obtained from a number of collaborating laboratories. We have identified one serum which has high levels of HIV-1 antibody but does not enhance infection at dilutions beyond the neutralization endpoint. There are no obvious differences in western blots in the antibodies to HIV-1 structural antigens between this serum and the other sera which neutralize HIV at low dilutions but enhance infection at dilutions above the neutralization endpoint.

# 2. <u>HIV-1 specific cytotoxic T lymphocyte responses</u>.

a) Autologous EBV transformed B cell lines infected with Vaccinia gp 160 hybird virus (obtained from B. Moss) as target cells.

We have established 20 autologous EBV transformed B cell lines from HIV-1 antibody positive donors. We are assessing whether the peripheral blood lymphocytes of these HIV-1 antibody-positive donors contain HIV-1 specific CTL, as reported by Walker, et al. We have found 2 donors' PBL that have some specific lytic activity of their

3

autologous, EBV-transformed B cell lines infected with the Vaccinia gp 160 hybrid virus, but 8 other donors PBL do not. Most of the donors' PBL lyse their autologous EBV-transformed cell lines to a high degree, so this makes it difficult to use these donors' B cell lines as target cells for HIV specific killing.

b. Stimulation of HIV-1 specific T cells.

• • • • •

We have stimulated the PBL of 20 HIV antibody-positive donors with live HIV-1 (HTLV-III<sub>B</sub>) virus, and only 30% respond. These donors were selected because they appeared to be in Walter Reed Stages 1 or 2. Thus, our results with live virus HIV-1 antigen are similar to those published by Wahren et al using a heat killed HTLV III<sub>B</sub> antigen.

In an effort to improve the T cell response of the PBL of HIV-1 antibody positive donors, we have added IL-2 to these assays, and tested the PBL of several of the non-responders again. Our results show that I1-2 at high concentrations non-specifically increases lymphocyte growth but at low concentrations specifically augments the growth of HIV-1 specific lymphocytes.

We will continue to analyse T cell responses to HIV-1, and we hope to establish human T cell lines for epitope mapping now that we are succeeding in showing higher levels of HIV-1 specific stimulation.

4

# Best Available Copy